The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study
Abstract
Objective: To investigate the efficacy and safety of increasing doses of cathine (nor-pseudoephedrine) as a weight-lowering agent in patients with obesity. Methods: Overweight and obese patients (n = 241, mean BMI 34.6 ± 3.4 kg/m²) were randomly allocated to one of three doses of cathine (16 mg, 32 mg, 53.3 mg) or placebo in addition to a multimodal lifestyle intervention program in a multicenter, double-blind, controlled, dose-finding study for 24 weeks. Primary outcome was weight loss. Results: Treatment with the 3 doses of cathine resulted in a significantly greater weight loss compared to placebo over 24 weeks: 6.5 ± 4.2 kg for 16 mg cathine, 6.2 ± 4.7 kg for 32 mg cathine, and 9.1 ± 5.4 kg for 53.3 mg cathine versus 2.4 ± 4.4 kg for placebo (each p < 0.01, ANCOVA). The percentage of patients losing > 5% / >10% of initial body weight was significantly greater for all doses of cathine than for placebo (each p < 0.01, chi-square test). Heart rate increased dose-dependently (by 1.2 bpm under 16 mg, 5.8 bpm under 32 mg, and 6.2 bpm under 53.3 mg cathine), but no suspected unexpected serious adverse reactions were noted. The overall dropout rate was 24.9%, with the highest rate in the placebo group (42.3%). Conclusion: Cathine appears to be an effective weight-lowering agent for adjunct treatment of obesity, but additional clinical studies on its efficacy and safety are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Research works printed but not linked: 12
- 10.1016/S0140-6736(16)30054-X · DOI · Paper page
- 10.1111/j.1463-1326.2010.01353.x · DOI
- 10.1111/jcpt.12177 · DOI
- 10.1159/000430801 · DOI
- 10.2165/00003495-200666120-00012 · DOI
- 10.1016/0163-7258(90)90057-9 · DOI · Paper page
- 10.1007/s00508-009-1259-7 · DOI · Paper page
- 10.1016/j.jep.2010.07.001 · DOI · Paper page
- 10.1002/dta.313 · DOI · Paper page
- 10.1055/s-2004-817934 · DOI
- 10.1016/S0022-3999(01)00296-3 · DOI · Paper page
- 10.1038/sj.ijo.0802887 · DOI
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citationChen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
Metadata
- Authors
- Hauner, H., Hastreiter, L., Werdier, D., Chen-Stute, A., Scholze, J., & Blüher, M.
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 10
- Issue
- 4
- Pages
- 407-419
- ISSN
- 1662-4025
- 1662-4033
- Cited by
- 32
- References
- 2
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study. https://app.cochat.ai/papers/10.1159/000478098
- The paper
- Hauner, H., Hastreiter, L., Werdier, D., Chen-Stute, A., Scholze, J., & Blüher, M. (2017). Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study. Obesity Facts. https://doi.org/10.1159/000478098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.